How Lurbinectedin Is Administered
Lurbinectedin (brand name Zepzelca) is given as an intravenous (IV) infusion over 60 minutes every 21 days, typically as monotherapy for adults with metastatic small cell lung cancer (SCLC) that progressed after platinum-based chemotherapy.[1] It's administered in a hospital or clinic by healthcare professionals using a dedicated IV line to avoid interactions with other drugs.
Dosage and Cycle Details
The standard dose is 3.2 mg/m² (up to a maximum of 4 mg or 600 mg, whichever is lower) per cycle, adjusted for body surface area. Premedication includes antiemetics like dexamethasone, serotonin antagonists, and NK1 receptor antagonists to prevent nausea and vomiting. Cycles repeat every 21 days if blood counts recover (absolute neutrophil count ≥1.5 × 10⁹/L and platelet count ≥100 × 10⁹/L).[1]
Role in Chemotherapy Regimens
Lurbinectedin is FDA-approved for second-line use after platinum failure, not frontline chemotherapy. It's often sequenced after regimens like carboplatin-etoposide, with no standard combinations approved. In trials like IMphase, it showed 35% overall response rate as monotherapy.[1][2] Liver function tests and complete blood counts are monitored before each dose.
Common Side Effects During Infusion
Patients report fatigue, nausea, decreased appetite, and myelosuppression (low blood counts) as frequent issues. Infusion-related reactions are rare but can include fever or chills—stop infusion if severe.[1] Hematologic toxicity may delay cycles or require dose reductions to 2.2 mg/m² or 1.5 mg/m².
Patient Preparation and Monitoring
Hydration isn't routinely required, but antiemetics start 30-60 minutes pre-infusion. Avoid strong CYP3A inhibitors/inducers, which alter drug levels. Treatment continues until disease progression or unacceptable toxicity.[1]
[1]: Zepzelca Prescribing Information (FDA)
[2]: IMphase Trial (NEJM)